Thursday, 31 August 2017

Work with us_Part time opportunities for Mumbai based students

We are looking for Mumbai/ Thane/ Navi Mumbai students to join our team of professionals. If you want to shine in your career in the years ahead or study abroad, this is a golden opportunity to make your base solid. Think beyond the lectures/ practicals/ seminars/ workshops/ conferences. Come join us for an exciting opportunity ahead. 

Pharma Literati is pleased to announce the internship opportunities for undergraduate/ post-graduate students in pharmacy/ life sciences domain. 

Looking for passionate, career-focused, highly motivated individuals who wish to join the dynamic team of Pharma Literati. 
  • Profile: The students would work with a dynamic team of professionals and help Pharma Literati team in their endeavors to manage and co-ordinate
-        Pharma Innovation Yatra;
-        CPIPR course;
-    Upcoming courses under the aegis of Pharma Literati Centre of Excellence for Pharma Education;
-        Conducting telephonic/ In person interviews of industry stalwarts;
-        Joint ventures with the partners;
Also, the students would work as bloggers during this tenure. 
  • Location: Work from home;
  • Tenure: As mutually agreed;
  • Joining date: As early as possible;
  • Requirements: Internet connection and laptop/desktop at home;
  • Stipend: Depending upon the institute and contribution to the blog; 
  • Eligibility: B. Pharm/ M. Pharm/ MBA students with basic understanding of internet and Microsoft Office;
  • What would students gain: 
-        Certificate to be provided to the intern on successful completion of internship;
-        If you love travelling once in a while, this is for you;
-       You would be dealing with the who’s who of the academia and industry on behalf of Pharma Literati;
-        Learn the best of the management lessons with live experience working with a mentor;
-        We would take care of your travel expenses (for activities related to pharma literati), telephone expenses and food expenses;
-       Exciting opportunities to represent Pharma Literati at various forums and be part of various educational and other activities.

Send your CVs to before 15th September, 2017. 1/2 positions available.

***Meet us for a cup of Coffee at (Starbucks, CafĂ© Coffee Day, Barista) a convenient place to discuss this in detail. 

Wednesday, 30 August 2017

Share your Internship experience and register free for one of our courses

In another new effort to bridge gap between industry and academia, team pharma literati is launching a new regular feature for our readers. 

Are you an intern? Have you completed your internship at any institute or company or R & D or Marketing recently? Here is a golden opportunity for all to share your experience of internship with the world. 

Those who finished their internship after 1st Jan. 2017 are eligible for this feature. 

What would you get?
1. A free (No conditions applied, it's absolutely free) registration to one of our courses under the aegis of Pharma Literati Centre of Excellence for Pharma Education.

2. Your internship experience would be published along with your name and photograph on Pharma Literati blog. 

3. You get an alumni status for Pharma Literati Centre of Excellence for Pharma Education.

How would the pharma community get benefited?
1. The pharma community gets benefited, especially the students by your your internship experience.

2. The students get idea about simple things like, how to approach for internship, what is the job profile like and the like.

How shall I share my experience?
We have a simple questionnaire meant for you. You can simple fill the questionnaire and that's it. If your experience is published via Pharma Literati blog, you would win a free registration for a course of your choice. The currently available course is CPIPR (Certificate Course in Pharmaceutical Intellectual Property Rights.)

Monday, 28 August 2017

Meeting on draft pharma policy called in New Delhi on Aug 30 with stakeholders

A day-long meet on draft pharmaceutical policy is called by department of pharmaceuticals (DoP) on August 30 in New Delhi to discuss key aspects of the policy with representative bodies of pharmaceutical industry and trade.

Representatives from IPA, IDMA, BDMA, FOPE, OPPI, CIPI, FICCI, ASSOCHAM, CII, PHD, Pharmexcil, AIDAN, Nathealth, Prayas, Consumer Connexion, LOCOST, JSA, AIOCD, AICDF, Consumer India have been invited for the conference.

The inaugural session of the  meet will be addressed by Sudhansh Pant, joint secretary of DoP, Jai Priye Prakash, secretary of DoP, CK Mishra, secretary of ministry of health and family welfare, Ramesh Abhishek, secretary of department of industrial policy and promotion, Rita Teaotia, secretary, department of commerce, Ajay Narayan Jha, secretary, ministry of environment, forests and climate change, Bhpendra Singh, chairman of National Pharmaceutical Pricing Authority, Rajneesh Tingal, joint secretary of DoP.

Divided into four sessions, the symposium will feature eight roundtable discussions on varied issues pertaining to pharmaceutical sector. The first session will have roundtable discussion on “Understanding and analyzing the extent of India's dependence on imports for key APIs (especially from China) followed by another roundtable discussion on “environmental issue”.

The second session will also have two roundtable discussions on “Quality standards for exports of pharmaceutical products” and “R&D, drug discovery and innovation of new molecules” followed by roundtable discussions on “Contract/loan licensing manufacturing” and “Promotion of generic formulations” in third session. The fourth session will witness roundtable discussions on two contentious issues in pharma segment such as “Intellectual property rights issues” and “Pricing aspects including functioning of NPPA”.

Complimentary registrations for CPIPR

Team pharma Literati has recently announced the launch of Certificate course in Pharmaceutical Intellectual Property Rights (CPIPR). 

We are providing complimentary registrations for 

1. Winners of 1st Annual Pharma Literati essay contest:

2. Faculty members who were part of workshop on "Teaching with animations"

3. One complimentary registration for the institutes who were part of Pharma Innovation yatra. 

Emails have been already sent to the concerned with the promo code details. If anyone hasn't received the email, please get in touch with us at

Thursday, 24 August 2017

Registration form for Certificate course in Pharmaceutical Intellectual Property Rights (CPIPR)

Registration forms for Certificate course in Pharmaceutical Intellectual Property Rights (CPIPR) are now available. CPIPR is a unique initiative under the aegis of Pharma Literati centre of Excellence of Pharma Education.

There are limited registrations available for the course. For discounts and any further enquiries write back to us to or call us on 8850949256.

Frequently asked questions:

What is the last date of registration?
15th September 2017.

How shall I make the payment?
Online transfers and cheques or DDs are accepted. Please send an email, call or WhatsApp for the account details. The account details are available on the link of registration form.  

How would I get the notifications about the courses?
Via registered mobile number, you would receive the SMS notifications about,
·       Lecture date and time;
·       New module being uploaded;
·       Any other notice;

How would the lectures be conducted?
Via digital platforms. The messages would be received in advance about the date, time and the platform to be used.

What if I skip the lecture on the given date?
You can still watch the recorded lecture later as per your convenience.

Can I download the training material?
Yes. However, as the material is copyright protected, it can not be shared with anyone else.

How would I get my certificate after clearing the exam?
Via courier as per the address provided by you at the time of registration.

Monday, 21 August 2017

Learn IPR with the experts_About faculty of CPIPR

We have recently announced the launch of Certificate course in Pharmaceutical Intellectual Property Rights (CPIPR). The faculty for the same is Mr. Mayank Gupta.

Mr. Mayank Gupta is currently serving as Manager, IPR, Sun Pharma. He carries with him more than 8 years of experience in IPR with leading pharmaceutical organizations like Glenmark and Lupin pharma. M-Pharm from BITS, Pilani, Mayank is an IPR expert with the expertise in generics as well as innovation. He is also a registered patent agent with the Indian Patent Office. 

For details of the course, please see:

Certificate course in Pharmaceutical Intellectual Property Rights (CPIPR)

Pharma Literati Centre of Excellence of Pharma Education is pleased to announce its first offering. First of its kind of a course being delivered by the industry experts "Certificate Course in Pharmaceutical Intellectual Property Rights (CPIPR)". 

For whom?
  1. Pharmacy/ Chemistry/ Biosciences/ Life sciences/ Biotechnology/ Zoology/ Botany students in undergraduate/ post graduate / PhD/ Research fellows;
  2. Faculties form any of these streams;
  3. Industry professionals** from Pharma/ Biotechnology/ Life sciences;
  4. Anyone who is willing to make a career in R & D; Business development; International Business; Drug discovery; Generic drug development; Academic research; Regulatory affairs; Intellectual Property Rights and the like;
  5. Students willing to pursue higher studies in USA/Europe/ Canada/ Australia/ Russia/ Korea/ Japan/ other countries as PhD/ MBA/ MS/ Masters.
** Since this is a basic level course, it is designed for non-IPR professionals.

Significance of the course:
Life sciences is going through a transition phase with abundant activities in Research and Development arena. The increased focus to R & D in academia and industries has led to Intellectual Property Rights at the centerstage. The increase in patenting activities by the academia is a welcome sign for bridging the industry academia gap.

We at Pharma Literati are proud to be associated with many institutes in these activities and are on a mission called “Pharma Innovation Yatra, 2017”. As a part of these activities, we are proud to announce another effort to fill the vacuum which was observed in many institutes during this yatra by launching this course on IPR.

The upgraded syllabus of pharmacy at many institutes, universities includes IPR as a core subject or a part of the subject. However, the thorough understanding of the subject is needed considering its global nature. We believe the course would be a stepping stone in this long journey of Innovation.

1.    Specially designed basic level course for Patents and IPR;
2.    Customized for the pharmaceutical industry;
3.    Delivered by the faculty from the industry;
4.  This is an effort of bridging the industry - academia gap highlighting the significance of Intellectual Property Rights to the pharmacy professionals and students;

Course contents:
This course consists 6 different modules:
The pharmaceutical business
The module discusses the working of the pharmaceutical industry and the business models globally.
The pharmaceutical R & D
This module discusses the working of the R & D teams.
Intellectual Property Rights: Introduction
This module discusses various forms of Intellectual Property Rights.
IPR: With specific reference to pharma
This module discusses the patentability criteria with specific reference to pharmaceutical industry including various related terminologies.
IPR: Indian patent scenario
This module discussed the Indian patent scenario.
Patent commercialization and licensing
This module discusses the basics of patent licensing and commercialization of the invention.

Course duration:
3 months including the live lectures.

Course methodology:
·      The course consists of 6 different modules. The course contents would be available online in the PDF format.
·       Fortnightly, one module would be uploaded on the website and would be available to study. The students can also download the contents for the future reference.
·       For each module, there would be one session by course faculty.
·     The students have an option to be part of the WhatsApp group for discussion and solving the queries for the course.
·      At the end of the course, an online examination would be conducted. The examination would be based on the contents of the modules and the news items on the Pharma Literati blog. The questions would be multiple choice questions. Students need to subscribe or visit to the blog free of cost.
·       The successful students would receive the certificate at their address of correspondence.

Benefits of the course:
·     Certificate would be provided to the students completing the course successfully.
·     Alumni status of Pharma Literati’s centre of excellence of pharma education, providing free access to the events and all the competitions.
·       Interaction with the industry experts and their live experiences.
·       Assistance in patent filing for the inventions at the institutes.
·       Access to the events and programs of the partner institutes.
·       Discounts upto 35 % for the other courses of the centre of excellence.
·       Access to whatsapp group as member.

Course fees:
Fees for the students:     Rs. 6000 + 1080 (GST) = 7080 Rs.
For others:                       Rs. 8000 + 1440 (GST) = 9440 Rs.
Send an email to to know the mode of payment.

For discounts and free registrations, please write to us at

Sunday, 20 August 2017

Pharma Innovation Yatra at Konkan Gyanpeeth Rahul Dharkar College of Pharmacy and Research Institute, Karjat

On 19th August 2017, the Pharma Innovation Yatra reached the beautiful city of Karjat, near Mumbai. A session on creative thinking and innovation was conducted at the institute. This marks the 13th session of the Yatra, which is a Pharma Literati initiative. 

The sessions were attended by over 100 students of 3rd year and final year B. pharmacy. 

Pharma Innovation yatra is already conducted at various places in Maharashtra and Gujarat. 

Pharma Literati team is planning to conduct the session at various institutes in next couple of months. Five more sessions are in the pipeline in the upcoming month. We are still accepting the invites to conduct the sessions at various institutes. The programs are free of cost. Please write an email to if you wish us to conduct the program at your institute to confirm the date.

Friday, 18 August 2017

Draft pharma policy dilutes powers of pricing regulator

The prices of medicines will soon bend in the service to the government’s ‘ease of doing business’ and ‘Make in India’ programmes, if the proposals in the Draft Pharmaceutical Policy, 2017 are accepted.

The Draft Policy, which BusinessLine has seen, calls for ‘re-orientation’ of the Drug Price Control Order (DPCO) from “price-control to monitoring of drug prices”.

The Draft, which focuses heavily on prices of medicine, has proposed massive dilutions in the existing framework, which would give more control to the government over the operations of the National Pharmaceutical Pricing Authority (NPPA), which till now functions as an autonomous body.

It also attempts to strip the NPPA of some powers, for instance, once the price for a drug is fixed the pricing authority would not be allowed to revise them. The NPPA would also lose its power to cap the prices of in-patent medicines, and would be able to use its “emergency powers” only on the government’s orders.

“This Policy would significantly contribute to the Ease of Doing Business in the pharmaceutical sector… The ‘Make-in-India’ programme would also get an impetus by the actions,” the draft policy says.

The Authority is set to lose its autonomy with increase in interference from the government. While the policy says, “The regulator and the government would be two distinct agencies. The government shall not be the regulator and the regulator shall not be the government,” yet a government-appointed advisory body, with representation from the government, industry, as well as civil society, is being proposed.

The NPPA brought down the prices of life-saving cardiac stent down by over 80 per cent in some instances and on Wednesday capped the prices of knee implants by nearly 69 per cent (for some types), besides several other medicines.

The industry is also wary of the proposed changes in the law. DG Shah, Secretary General of the Indian Pharmaceutical Alliance said, “This could, possibly, be one of the most difficult policies for the industry. It would push up costs and reduce margins and increase pressure on pricing.”

He said that while the draft policy appears to be envisaging a much wider span of control, some of the steps such as eliminating third-party manufacturing and loan licencing would hit the industry as well as the availability of medicines. “What is the extent of loan licencing in the country and what will be the impact? Preliminary calculations show that one-third of the industry is under loan licencing. If it is phased out how many people would lose employment and how would you ensure availability of these medicines?”

On the issue of restricting price control only to off-patent medicines, Shah said, “Only multinationals hold patents, which would not be under price control. While the rest of the market, which produce cheap medicines would be under price control. It says DPCO would look at monitoring prices instead of capping. What does that mean? The policy has not been thought through.”

Centre’s understanding of pharma industry wrong, not surprising draft policy so flawed

Over the years, with more and more of the Indian pharmaceuticals industry subjected to different forms of price control, firms have focused more on the overseas business - from 43% of industry revenues in FY11, the domestic industry has been reduced to 34% in FY16. While the government has seized upon this lowering of growth of the domestic industry - in its draft pharmaceuticals policy - it has misdiagnosed the problem, compounded this with goals that are contradictory, and come out with a diagnosis designed to make things worse. After prefacing the statement by saying “India is also called the ‘pharmacy of the world’ and renowned for very high quality drugs at very cost competitive prices”, the rest of the policy is dedicated to finding ways to tighten existing price controls. That these price controls are the reason for many of the problems the policy talks of - less emphasis on R&D, excessive use of foreign raw materials and non-adherence to quality standards - escapes the policymakers’ attention.

That is odd since, while lamenting the import dependence for raw materials/intermediates, the policy talks of how, in the 1950s and 1960s, PSUs were doing a good job of producing these - then, the policy says, “the Drug Price (Display & Control) Order 1966 put 18 APIs (raw materials) under price control … from 1996 … imported APIs and Intermediates started becoming hugely lucrative as a price cap on drugs forced the manufacturers … to obtain the cheapest raw material with the basic minimum efficacy/quality”. If the policy recognises the impact of price controls on APIs, it must realise the same translates to the rest of the industry and that, without high enough profits, there will be a “disproportionate focus on generic formulations to the point of exclusion of lack of adequate R&D”. This relationship is, once again, recognised when, as a way to encourage local API manufacture, the policy prescribes that formulations based on these can be taken out of price control for five years and that graded relief can be given based on the level of local APIs.

There is little doubt there are a lot of spurious drugs and policies like commissions to doctors are unhealthy, but these have to be tackled by better policing of quality/standards, not by prescribing trade margins as the draft policy proposes or by bemoaning the fact that while India has about 2,500 pharmacopeial salts, it has “60,000 brand names with varying prices”. Instead of trying to enforce “one-drug-one-brand-name-one-price” as a policy - copied from GST’s ‘one-country-one-tax’? - it would be better to focus on ensuring all medicine conform to certain standards. Given the draft is so flawed, getting firm facts - saying “65% of the medical costs are on drugs” is pure fiction - will help formulate a better policy. Wanting more R&D and new molecules is good, but look at the margins of such companies overseas and the cost of such drugs. Is the government willing to allow such pricing? Certainly, the concessional import duties being promised to encourage R&D can’t substitute for the huge costs involved. Similarly, before tightening controls further, look at whether India’s prices are high or low - more so when there are dozens of manufacturers for most drugs. If the government finds - and chances are that it will - that well-known brands tend to be of a superior quality, it will realise there are definite benefits from brand-building. Creating ‘a level playing field’ by prescribing trade margins, as the policy wants to do, is a prescription for even lower quality drugs since both top-rung and fly-by-night operators will have the same margins.

Thursday, 17 August 2017

INDUSTRY - ACADEMIA CONCLAVE on Addressing National Trends in Harmonizing Norms in Drug Research

Addressing National Trends in Harmonizing Norms in Drug Research
CDRI, Lucknow, Uttar Pradesh
15th and 16th September 2017
For whom
Stakeholders in the discovery of small-molecule drugs, phytopharmaceuticals, formulations etc
31st August 2017